Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1967 1
1970 1
1972 1
1973 1
1974 1
1976 2
1977 2
1978 2
1979 2
1980 2
1981 3
1982 4
1983 1
1984 2
1985 3
1986 2
1987 6
1988 4
1989 6
1990 2
1991 4
1992 10
1993 5
1994 7
1995 7
1996 6
1997 12
1998 16
1999 6
2000 4
2001 5
2002 9
2003 7
2004 11
2005 9
2006 13
2007 5
2008 9
2009 8
2010 4
2011 11
2012 13
2013 16
2014 15
2015 9
2016 12
2017 20
2018 15
2019 14
2020 10
2021 9
2022 10
2023 6

Text availability

Article attribute

Article type

Publication date

Search Results

337 results

Results by year

Filters applied: Meta-Analysis, Randomized Controlled Trial. Clear all
Page 1
Acetazolamide in Acute Decompensated Heart Failure with Volume Overload.
Mullens W, Dauw J, Martens P, Verbrugge FH, Nijst P, Meekers E, Tartaglia K, Chenot F, Moubayed S, Dierckx R, Blouard P, Troisfontaines P, Derthoo D, Smolders W, Bruckers L, Droogne W, Ter Maaten JM, Damman K, Lassus J, Mebazaa A, Filippatos G, Ruschitzka F, Dupont M; ADVOR Study Group. Mullens W, et al. N Engl J Med. 2022 Sep 29;387(13):1185-1195. doi: 10.1056/NEJMoa2203094. Epub 2022 Aug 27. N Engl J Med. 2022. PMID: 36027559 Clinical Trial.
Successful decongestion occurred in 108 of 256 patients (42.2%) in the acetazolamide group and in 79 of 259 (30.5%) in the placebo group (risk ratio, 1.46; 95% confidence interval [CI], 1.17 to 1.82; P<0.001). ...Acetazolamide treatment was associated with higher …
Successful decongestion occurred in 108 of 256 patients (42.2%) in the acetazolamide group and in 79 of 259 (30.5%) in the placebo gr …
Acetazolamide to increase natriuresis in congestive heart failure at high risk for diuretic resistance.
Verbrugge FH, Martens P, Ameloot K, Haemels V, Penders J, Dupont M, Tang WHW, Droogné W, Mullens W. Verbrugge FH, et al. Eur J Heart Fail. 2019 Nov;21(11):1415-1422. doi: 10.1002/ejhf.1478. Epub 2019 May 9. Eur J Heart Fail. 2019. PMID: 31074184 Free article. Clinical Trial.
AIMS: To investigate the effects of acetazolamide on natriuresis, decongestion, kidney function and neurohumoral activation in acute heart failure (AHF). ...CONCLUSION: Addition of acetazolamide increases the natriuretic response to loop diuretics compared to an inc …
AIMS: To investigate the effects of acetazolamide on natriuresis, decongestion, kidney function and neurohumoral activation in acute …
Acetazolamide in Decompensated Heart Failure with Volume Overload trial (ADVOR): baseline characteristics.
Mullens W, Dauw J, Martens P, Meekers E, Nijst P, Verbrugge FH, Chenot F, Moubayed S, Dierckx R, Blouard P, Derthoo D, Smolders W, Ector B, Hulselmans M, Lochy S, Raes D, Van Craenenbroeck E, Vandekerckhove H, Hofkens PJ, Goossens K, Pouleur AC, De Ceuninck M, Gabriel L, Timmermans P, Prihadi EA, Van Durme F, Depauw M, Vervloet D, Viaene E, Vachiery JL, Tartaglia K, Ter Maaten JM, Bruckers L, Droogne W, Troisfontaines P, Damman K, Lassus J, Mebazaa A, Filippatos G, Ruschitzka F, Dupont M. Mullens W, et al. Eur J Heart Fail. 2022 Sep;24(9):1601-1610. doi: 10.1002/ejhf.2587. Epub 2022 Jul 12. Eur J Heart Fail. 2022. PMID: 35733283 Clinical Trial.
AIMS: To describe the baseline characteristics of participants in the Acetazolamide in Decompensated Heart Failure with Volume Overload (ADVOR) trial and compare these with other contemporary diuretic trials in acute heart failure (AHF). ...CONCLUSION: ADVOR is the largest …
AIMS: To describe the baseline characteristics of participants in the Acetazolamide in Decompensated Heart Failure with Volume Overlo …
Rationale and design of the ADVOR (Acetazolamide in Decompensated Heart Failure with Volume Overload) trial.
Mullens W, Verbrugge FH, Nijst P, Martens P, Tartaglia K, Theunissen E, Bruckers L, Droogne W, Troisfontaines P, Damman K, Lassus J, Mebazaa A, Filippatos G, Ruschitzka F, Dupont M. Mullens W, et al. Eur J Heart Fail. 2018 Nov;20(11):1591-1600. doi: 10.1002/ejhf.1307. Epub 2018 Sep 21. Eur J Heart Fail. 2018. PMID: 30238574 Free article. Clinical Trial.
AIMS: Decisive evidence on the optimal diuretic agent, dosing schedule, and administration route is lacking in acute heart failure (AHF) with congestion. The Acetazolamide in Decompensated heart failure with Volume OveRload (ADVOR) trial is designed to test the hypothesis …
AIMS: Decisive evidence on the optimal diuretic agent, dosing schedule, and administration route is lacking in acute heart failure (AHF) wit …
Acetazolamide for OSA and Central Sleep Apnea: A Comprehensive Systematic Review and Meta-Analysis.
Schmickl CN, Landry SA, Orr JE, Chin K, Murase K, Verbraecken J, Javaheri S, Edwards BA, Owens RL, Malhotra A. Schmickl CN, et al. Chest. 2020 Dec;158(6):2632-2645. doi: 10.1016/j.chest.2020.06.078. Epub 2020 Aug 5. Chest. 2020. PMID: 32768459 Free PMC article.
Acetazolamide doses ranged from 36 to 1000 mg/d and treatment duration from 1 to 90 d (median, 6 d). ...INTERPRETATION: Short-term acetazolamide improved both OSA and CSA. Rigorous studies with long-term follow up are warranted to assess Acetazolamide's value …
Acetazolamide doses ranged from 36 to 1000 mg/d and treatment duration from 1 to 90 d (median, 6 d). ...INTERPRETATION: Short-term …
Effect of acetazolamide on visual function in patients with idiopathic intracranial hypertension and mild visual loss: the idiopathic intracranial hypertension treatment trial.
NORDIC Idiopathic Intracranial Hypertension Study Group Writing Committee; Wall M, McDermott MP, Kieburtz KD, Corbett JJ, Feldon SE, Friedman DI, Katz DM, Keltner JL, Schron EB, Kupersmith MJ. NORDIC Idiopathic Intracranial Hypertension Study Group Writing Committee, et al. JAMA. 2014 Apr 23-30;311(16):1641-51. doi: 10.1001/jama.2014.3312. JAMA. 2014. PMID: 24756514 Free PMC article. Clinical Trial.

Mean improvements in papilledema grade (acetazolamide: -1.31, from 2.76 to 1.45; placebo: -0.61, from 2.76 to 2.15; treatment effect, -0.70; 95% CI, -0.99 to -0.41; P < .001) and vision-related quality of life as measured by the National Eye Institute VFQ-25 (acetazo

…
Mean improvements in papilledema grade (acetazolamide: -1.31, from 2.76 to 1.45; placebo: -0.61, from 2.76 to 2.15; treatment effect, …
Acetazolamide for the prevention of acute mountain sickness--a systematic review and meta-analysis.
Ritchie ND, Baggott AV, Andrew Todd WT. Ritchie ND, et al. J Travel Med. 2012 Sep-Oct;19(5):298-307. doi: 10.1111/j.1708-8305.2012.00629.x. Epub 2012 Jul 30. J Travel Med. 2012. PMID: 22943270 Free article. Review.
Primary end point was difference in incidence of AMS between acetazolamide and placebo groups. RESULTS: Acetazolamide prophylaxis was associated with a 48% relative-risk reduction compared to placebo. ...One study found that adverse effects of acetazolamide w …
Primary end point was difference in incidence of AMS between acetazolamide and placebo groups. RESULTS: Acetazolamide prophyla …
Decongestion With Acetazolamide in Acute Decompensated Heart Failure Across the Spectrum of Left Ventricular Ejection Fraction: A Prespecified Analysis From the ADVOR Trial.
Martens P, Dauw J, Verbrugge FH, Nijst P, Meekers E, Augusto SN Jr, Ter Maaten JM, Damman K, Mebazaa A, Filippatos G, Ruschitzka F, Tang WHW, Dupont M, Mullens W. Martens P, et al. Circulation. 2023 Jan 17;147(3):201-211. doi: 10.1161/CIRCULATIONAHA.122.062486. Epub 2022 Nov 6. Circulation. 2023. PMID: 36335479 Clinical Trial.
BACKGROUND: Acetazolamide inhibits proximal tubular sodium reabsorption and improved decongestion in the ADVOR (Acetazolamide in Decompensated Heart Failure with Volume Overload) trial. It remains unclear whether the decongestive effects of acetazolamide diff …
BACKGROUND: Acetazolamide inhibits proximal tubular sodium reabsorption and improved decongestion in the ADVOR (Acetazolamide …
Effects of acetazolamide on pulmonary artery pressure and prevention of high-altitude pulmonary edema after rapid active ascent to 4,559 m.
Berger MM, Sareban M, Schiefer LM, Swenson KE, Treff F, Schäfer L, Schmidt P, Schimke MM, Paar M, Niebauer J, Cogo A, Kriemler S, Schwery S, Pickerodt PA, Mayer B, Bärtsch P, Swenson ER. Berger MM, et al. J Appl Physiol (1985). 2022 Jun 1;132(6):1361-1369. doi: 10.1152/japplphysiol.00806.2021. Epub 2022 May 5. J Appl Physiol (1985). 2022. PMID: 35511718 Clinical Trial.
Acetazolamide prevents acute mountain sickness (AMS) by inhibition of carbonic anhydrase. ...Arterial Po(2) fell to 36 9 mmHg (P < 0.001) and was 8.5 mmHg higher with acetazolamide at high altitude (P = 0.025). At high altitude, the LLS and AMS-C score remained l …
Acetazolamide prevents acute mountain sickness (AMS) by inhibition of carbonic anhydrase. ...Arterial Po(2) fell to 36 9 mmHg (P < …
The effect of acetazolamide on sleep apnea at high altitude: a systematic review and meta-analysis.
Liu HM, Chiang IJ, Kuo KN, Liou CM, Chen C. Liu HM, et al. Ther Adv Respir Dis. 2017 Jan;11(1):20-29. doi: 10.1177/1753465816677006. Epub 2016 Nov 15. Ther Adv Respir Dis. 2017. PMID: 28043212 Free PMC article. Review.
BACKGROUND: Acetazolamide has been investigated for treating sleep apnea in newcomers ascending to high altitude. ...CONCLUSIONS: Acetazolamide improves sleep apnea at high altitude by decreasing AHI and percentage of periodic breathing time and increasing nocturnal …
BACKGROUND: Acetazolamide has been investigated for treating sleep apnea in newcomers ascending to high altitude. ...CONCLUSIONS: …
337 results

Searches related to "acetazolamide"